Repligen | RGEN - Equity Capital And Reserves


Repligen reported $2.11B in Equity Capital and Reserves for its fiscal quarter ending in December of 2025.





Equity Capital And Reserves Change Date
Agilent USD 6.91B 167M Dec/2025
Align Technology USD 3.96B 44.68M Sep/2025
Bio Techne USD 2.01B 45.18M Dec/2025
BioMarin Pharmaceutical USD 6.09B 30.29M Dec/2025
Bristol-Myers Squibb USD 18.55B 1.06B Sep/2025
Bruker USD 2.49B 625.6M Sep/2025
Charles River Laboratories USD 3.16B 240.82M Dec/2025
Danaher USD 52.53B 1.46B Dec/2025
Dentsply International USD 1.34B 139M Dec/2025
General Electric Aerospace USD 18.9B 86M Dec/2025
Henry Schein USD 3.24B 116M Dec/2025
Illumina USD 2.72B 342M Dec/2025
IQVIA Holdings USD 6.5B 343M Dec/2025
Mettler Toledo International USD -23.64M 225.56M Dec/2025
Myriad Genetics USD 368M 4.8M Dec/2025
OraSure Technologies USD 340.83M 21.15M Dec/2025
Pacific Biosciences Of California USD 5.35M 30.74M Dec/2025
Pfizer USD 92.8B 4.11B Sep/2025
Repligen USD 2.11B 1.66B Dec/2025
Revvity USD 7.38B 180.27M Sep/2025
Standard Biotools USD 424.29M 24.63M Dec/2025
Thermo Fisher Scientific USD 53.54B 2.38B Dec/2025
Waters USD 2.56B 230.55M Dec/2025
West Pharmaceutical Services USD 3.18B 124.5M Dec/2025